Embedded Files
We regularly publish articles exploring AI-driven solutions' latest advancements, challenges, regulatory aspects, and philosophical concerns.
This section showcases our contributions as columnists, covering topics such as AI safety, explainable AI (xAI), governance, and the impact of AI on drug development and industrial applications.
Explore our published work to gain insights into how AI is transforming the industry, shaping policies, and driving innovation in life sciences.
2025
2025
The rise of multimodal language models in drug development
European Pharmaceutical Review · June 12, 2025Industry experts, Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos Velez reflect on the necessity to ensure data quality in order to gain full advantage from multimodal language models (MLMs).From siloed data to breakthroughs: multimodal AI in drug discovery
Drug Target Review · June 11, 2025Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
Quando l’AI riflette i bias: le disuguaglianze di genere nei dataset
Agenda Digitale · May 30, 2025I dataset utilizzati per addestrare l’intelligenza artificiale spesso sottorappresentano le donne, perpetuando discriminazioni storiche. Questo bias di genere negli algoritmi ha conseguenze concrete su salute, economia e diritti, richiedendo soluzioni sistemiche e inclusive.
Scoperta di nuovi farmaci: che succede se l’AI sostituisce il caso?
Agenda Digitale · April 23, 2025L’intelligenza artificiale sta trasformando la scoperta di farmaci, riducendo la casualità a favore della razionalità computazionale, sollevando interrogativi sull’equilibrio tra efficienza e innovazione scientifica
Early evidence and emerging trends: How AI is shaping drug discovery and clinical development
Drug Target Review · April 11, 2025Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
Navigating the AI revolution: a roadmap for pharma’s future
Drug Target Review · March 13, 2025AI-driven drug development, powered by advanced models and expanding data access, is becoming a reality. Learn why navigating regulatory hurdles and mastering biology’s inherent complexities are crucial to fully unlocking its potential.
Using clinical genomics and AI in drug development to elevate success
Drug Target Review · February 11, 2025How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.
Nuovi farmaci grazie all’AI: ecco le svolte attese nel 2025
Agenda Digitale · January 15, 2025L’integrazione tra genomica e AI sta rivoluzionando la scoperta di farmaci, riducendo costi e tempi. Le innovazioni tecnologiche e metodologiche, insieme a progressi normativi, hanno migliorato l’efficienza e la personalizzazione delle terapie, ridefinendo il paradigma farmaceutico.2024
2024
AI Hallucinations in Clinical Trial Predictions, Asset Valuations and Portfolio Management
Medium · February 26, 2024This article explores AI "hallucinations" in clinical trial predictions, asset valuations, and portfolio management within the pharmaceutical industry. It highlights how limited data, particularly in First-In-Class and rare disease drug development, can lead to AI generating incorrect but confident outputs. The authors emphasize the need for high-quality datasets and careful AI model contextualization.
New FDA Draft Guidance: Data Monitoring Committees In Clinical Trials
Clinical Leader · April 1, 2024The article discusses the FDA's new guidance on data monitoring committees (DMCs) in clinical trials, which reflects the increased use of DMCs, the expansion of their statutes, the implementation of adaptive clinical trial designs, and the globalization of medical product development. The guidance emphasizes the importance of DMC independence, its responsibilities, and the confidentiality of interim data.
Life Science Leader · June 7, 2024This article warns about AI "hallucinations," where AI generates incorrect but confident outputs due to issues like biased data. It discusses risks in areas like medical diagnoses, emphasizes prompt engineering and human oversight to mitigate these errors, and considers whether accepting some hallucinations is a viable business cost.
Correct But Misleading: AI Hallucinations In Complex Decision-Making
Life Science Leader · July 11, 2024This article discusses AI "hallucinations," where AI gives correct but misleading answers due to faulty reasoning or compensatory errors. It emphasizes the need for explainable AI (xAI) and rigorous verification to ensure the reliability and safety of AI systems in complex decision-making, especially in drug development, where even seemingly correct outcomes can be compromised.
'Explainambiguity:' When What You Think Is Not What You Get
Life Science Leader · September 6, 2024The article discusses the ambiguity surrounding "explainable AI" (xAI) in the pharmaceutical industry. It highlights the importance of xAI for building trust in AI outcomes, ensuring transparency, and improving risk management in drug development. The piece explores different types of explainability, use cases, and the challenges of defining and implementing xAI effectively, emphasizing the need for a risk-based approach.
AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development PART1
Life Science Leader · October 4, 2024The article explores how artificial intelligence (AI) is transforming drug discovery and development, accelerating timelines, reducing costs, and potentially increasing the likelihood of drug success in clinical trials. AI technologies and tools are discussed, with a focus on generative AI and its impact on research velocity.
AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development PART2
Life Science Leader · October 23, 2024The article explores how artificial intelligence (AI) is transforming drug discovery and development, accelerating timelines, reducing costs, and potentially increasing the likelihood of drug success in clinical trials. AI technologies and tools are discussed, with a focus on generative AI and its impact on research velocity.Scienze della vita: la svolta degli Small Language Model
Agenda Digitale · November 14, 2024Gli Small Language Models (SLMs) offrono soluzioni innovative nel settore Life Science, affrontando le sfide legate alla gestione dei dati complessi. Grazie alla loro efficienza e personalizzazione, migliorano l’analisi clinica e la sicurezza dei dati, promuovendo l’adozione globale della tecnologia nei contesti sanitariPage updated
Google Sites
Report abuse